Hedgehog IN-5

Modeling methods: Bleomycin (HY-108345) (3 mg/kg; Intratracheal injection for 8 days)-induced pulmonary fibrosis model in rats. Hedgehog IN-5 (5-30 mg/kg; Oral administration after 8 days of moulding; once daily for 2 weeks) inhibits the progression of pulmonary fibrosis induced by Bleomycin (HY-108345) in several pathological evaluation indexes in SD rat model of unilateral pulmonary fibrosis, significantly^[1].
Modeling methods: CCL4 (dissolved in olive oil at a dose of 0.5 μL/g; Oral administration; Three times a week for four weeks)-induced liver fibrosis model in C57BL/6 mice. Hedgehog IN-5 (5-20 mg/kg; Oral administration on the day of moulding; Once a day for 4 weeks) exhibits a certain trend of inhibiting CCl4-induced liver fibrosis. And primarily manifests as a reduction in hepatocyte degeneration and necrosis, as well as a decrease in fibrotic area in CCL4-induced liver fibrosis model in C57BL/6 mice^[1].
Hedgehog IN-5 (10-20 mg/kg, 20mg/kg (Combined with BIBF1120 (50 mg/kg); Oral administration; Once a day for 20 days) alone or in combination with BIBF1120 significantly inhibits bleomycin-induced lung tissue inflammation and fibrosis^[1].